-
公开(公告)号:US10851081B2
公开(公告)日:2020-12-01
申请号:US16861646
申请日:2020-04-29
申请人: Pfizer Inc.
发明人: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC分类号: C07D401/14 , C07D471/04 , A61K31/4545 , C07D487/04 , A61P3/00 , A61P15/10 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D413/14 , A61K31/496
摘要: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US09399626B2
公开(公告)日:2016-07-26
申请号:US14299497
申请日:2014-06-09
申请人: Pfizer Inc.
发明人: Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC分类号: C07D239/56 , A61K31/513 , A61K31/352 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/10 , C07D487/04 , C07D417/04 , C07D471/04 , A61K31/37
CPC分类号: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
摘要: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
摘要翻译: 髓过氧化物酶抑制剂,含有这些抑制剂的药物组合物以及这些抑制剂用于治疗例如心血管病症的用途。
-
公开(公告)号:US20130296351A1
公开(公告)日:2013-11-07
申请号:US13875604
申请日:2013-05-02
申请人: Pfizer Inc.
发明人: Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC分类号: C07D239/56 , A61K45/06 , A61K31/513
CPC分类号: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
摘要: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
摘要翻译: 髓过氧化物酶抑制剂,含有这些抑制剂的药物组合物以及这些抑制剂用于治疗例如心血管病症的用途。
-
公开(公告)号:US20210047298A1
公开(公告)日:2021-02-18
申请号:US17085534
申请日:2020-10-30
申请人: Pfizer Inc.
发明人: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC分类号: C07D401/14 , A61K31/496 , A61K31/4545 , C07D487/04 , A61P3/00 , A61P15/10 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D413/14 , C07D471/04
摘要: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20190119255A1
公开(公告)日:2019-04-25
申请号:US16220184
申请日:2018-12-14
申请人: Pfizer Inc.
发明人: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC分类号: C07D401/14 , A61K31/4545 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D471/04 , A61P15/10 , A61P3/00 , C07D487/04 , C07D413/14 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61K31/496
摘要: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20160304469A1
公开(公告)日:2016-10-20
申请号:US15191943
申请日:2016-06-24
申请人: Pfizer Inc.
发明人: Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC分类号: C07D239/56 , A61K45/06 , C07D401/04 , C07D405/04 , C07D403/04 , C07D471/04 , C07D409/04 , C07D417/04 , C07D405/10 , C07D405/06 , C07D403/06 , C07D403/10 , C07D401/06 , C07D413/06 , A61K31/5377 , C07D403/12 , A61K31/513
CPC分类号: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
摘要: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
公开(公告)号:US20210309646A1
公开(公告)日:2021-10-07
申请号:US17345064
申请日:2021-06-11
申请人: Pfizer Inc.
发明人: Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC分类号: C07D405/14 , C07D401/14 , A61K31/506 , A61K45/06 , C07D409/14
摘要: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号:US20200181127A1
公开(公告)日:2020-06-11
申请号:US16793441
申请日:2020-02-18
申请人: Pfizer Inc.
发明人: Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC分类号: C07D405/14 , C07D409/14 , A61K45/06 , A61K31/506 , C07D401/14
摘要: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号:US20180170908A1
公开(公告)日:2018-06-21
申请号:US15839901
申请日:2017-12-13
申请人: Pfizer Inc.
发明人: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC分类号: C07D401/14 , C07D471/04 , C07D405/14 , C07D413/14 , A61P3/10 , A61P25/28 , A61P25/02 , A61P13/12 , A61P43/00 , A61P3/04 , A61P1/16 , A61P9/10 , A61P19/02 , A61P25/16 , A61P19/06 , A61P15/10 , A61P17/06 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/30
CPC分类号: C07D401/14 , A61K31/4545 , A61K31/496 , A61P1/00 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/10 , A61P9/10 , A61P13/12 , A61P15/00 , A61P15/10 , A61P17/06 , A61P19/02 , A61P19/06 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P25/30 , A61P43/00 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
摘要: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US11512070B2
公开(公告)日:2022-11-29
申请号:US17085534
申请日:2020-10-30
申请人: Pfizer Inc.
发明人: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC分类号: C07D401/14 , A61K31/496 , A61K31/4545 , C07D487/04 , A61P3/00 , A61P15/10 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D413/14 , C07D471/04
摘要: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
-
-
-
-
-
-
-
-